- Home
- NUV vs TWST Comparison
NUV vs TWST Comparison
Compare NUV & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUV | TWST |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NUV | TWST |
|---|---|---|
| Price | $8.94 | $32.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.88 |
| AVG Volume (30 Days) | 464.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 02-02-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $7.86 | $23.30 |
| 52 Week High | $9.08 | $55.33 |
Technical Indicators
Market Signals| Indicator | NUV | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 57.27 |
| Support Level | $8.95 | $30.21 |
| Resistance Level | $9.03 | $33.75 |
| Average True Range (ATR) | 0.05 | 1.79 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 2.00 | 77.83 |
Price Performance
Historical ComparisonAbout NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.